Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + Rituximab Maintenance in Elderly MCL
NCT01865110Phase 3Completed
- Sponsor
- LYSARC
- Start
- Nov 2013
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of lenalidomide in mantle cell lymphoma (MCL), sponsored by LYSARC. Started Nov 2013; status: completed.
02
Drugs
lenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01865110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01865110.